Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Cetuximab is a standard-of-care treatment for RAS wild-type metastatic colorectal cancer (mCRC) but not for those harbor a KRAS mutation since MAPK pathway is constitutively activated. Nevertheless, cetuximab also exerts its effect by its immunomodulatory activity despite the presence of RAS mutatio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2019-02, Vol.9 (1), p.2589-2589, Article 2589
Hauptverfasser:	Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	45/29 45/77 692/4028/67/1504/1885 692/53/2423 82/1 82/51 Colorectal cancer Colorectal carcinoma Epidermal growth factor receptors Gene polymorphism Homozygotes Humanities and Social Sciences Immunomodulation Immunotherapy K-Ras protein KIR2DS4 protein MAP kinase Metastases Metastasis Monoclonal antibodies multidisciplinary Multivariate analysis Mutation Patients Potassium channels (inwardly-rectifying) Science Science (multidisciplinary) Targeted cancer therapy Typing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!